To bridge or not to bridge: that is the question. The argument FOR bridging therapy in patients on oral anticoagulants requiring temporary interruption for elective procedures.
Spyropoulos
Alex C
AC
Division of Hematology and Thromboembolism, Department of Medicine, Hamilton General Hospital, McMaster University, McMaster Clinic, 237 Barton Street East, Hamilton, ON, L8L 2X2, Canada. spyropa@mcmaster.ca
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D004334:Drug Administration Schedule; D017558:Elective Surgical Procedures; D019317:Evidence-Based Medicine; D006493:Heparin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D018579:Patient Selection; D019106:Postoperative Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors; D013514:Surgical Procedures, Operative / Q000009:adverse effects*; D013923:Thromboembolism / Q000517:prevention & control*; D014859:Warfarin / Q000008:administration & dosage* / Q000009:adverse effects
D000925:Anticoagulants; D014859:Warfarin; D006493:Heparin